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Abstract
Background—Treatment of comorbid chronic disease, such as depression, in people living with 
HIV/AIDS (PLWHA) increasingly falls to HIV treatment providers. Guidance in who will best 
respond to depression treatment and which patient-centered symptoms are best to target is limited.
Methods—Bivariable analyses were used to calculate hazard ratios for associations between 
baseline demographic, mental health-related, and HIV-related factors on time to first depression 
remission among PLWHA enrolled in a randomized trial of measurement-based antidepressant 
management. Time-updated factors also were analyzed at time of antidepressant (AD) initiation/
adjustment and 8 weeks post AD initiation/adjustment.
Results—Baseline comorbid depression and anxiety; comorbid depression, anxiety and 
substance abuse; and generalized anxiety disorder predicted a slower time to first remission. Being 
on ART but non-adherent, having panic disorder, having a history of a major depressive episode, 
or having been in HIV care for > 10 years prior to study initiation predicted a faster time to first 
remission. Sleep difficulty or fatigue at the time of AD initiation/adjustment predicted a slower 
time to remission. In non-remitters at 8 weeks post AD initiation/adjustment, sleep difficulty, 
anxiety, and fatigue each predicted a slower time to remission.
Limitations—Remission was determined by PHQ-9 scores, not diagnostic criteria. The results 
may apply only to depression recovery in this particular model of treatment. We conducted only 
exploratory analyses to determine magnitude of effects.
Conclusions—Baseline comorbid anxiety with or without substance abuse predicts slower time 
to depression remission among PLWHA treated in HIV clinics. Targeting anxiety or fatigue at the 
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time of AD initiation/adjustment or sleep difficulty, anxiety, and fatigue at 8 weeks post AD 
initiation/adjustment could shorten time to depression remission in this model.
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1. Background
The number of pepole living with HIV/AIDS (PLWHA) has grown rapidly over the past 
decade, largely due to increased access to and effectiveness of antiretroviral therapies (ART) 
(UNAIDS, 2012). As a result, life expectancies have increased and the burden of 
opportunistic infections has decreased (Bor et al., 2013; Jahn et al., 2008; Mills et al., 2011). 
An unforeseen and unwelcome consequence of these results is that the number of PLWHA 
who develop noncommunicable diseases has increased (Mocroft et al., 2002; Palella et al., 
2006). Included in this group are a spectrum of mental illnesses, including major depressive 
disorder. HIV infection is associated with an elevated prevalence of depression, affecting 
20–30% of PLWHA (Bing et al., 2001; Ciesla and Roberts, 2001). Various factors 
contribute to this higher prevalence, including high viral load, direct effects of the virus on 
the immune system, symptom burden, emotional reaction to the diagnosis, and social stigma 
(Atkinson et al., 2008; Bing et al., 2001; Lyketsos et al., 1996). Worldwide, depression in 
PLWHA is associated with decreased quality of life, reduced adherence to anti-retroviral 
medications, increased use and abuse of substances, and poor treatment outcomes, including 
increased utilization of services, more rapid decline in CD4 count, and increased mortality 
(Ickovics et al., 2001; Kacanek et al., 2010; Pence et al., 2007; Rubin et al., 2011; Uthman et 
al., 2014). Treatments for depression in PLWHA are similar to those in the general 
population, and they are similarly effacacious. Meta-analyses of randomized control trials of 
pharmacologic and group-therapy based treatments of depression in PLWHA showed effect 
sizes that are similar to those in the general population (Himelhoch and Medoff, 2005; 
Himelhoch et al., 2007).
While there has been an increased demand for mental health care services for PLWHA, the 
supply of specialty mental health care providers has not kept pace. As a result, the 
identification and management of depression in PLWHA often falls to HIV care providers. 
The challenges of identifying, effectively treating, and monitoring depressive symptoms in 
these clinical settings can require significant resources. Consequently, models of care that 
integrate medical and psychiatric care have the potential to provide cost-effective care in 
HIV clinic settings (Hyle et al., 2014). Indeed, the National AIDS Policy discusses the need 
for making the HIV clinic the “medical home” where patients can receive all of their 
medical and mental health care in one setting (Adams et al., 2012; Policy, 2010). Integrated 
care approaches are cost-effective in treating depression with resultant improvements in 
other noncommunicable diseases in other populations (Bogner and de Vries, 2008; Katon et 
al., 2010; Katon et al., 2004; Pyne et al., 2011). However, some PLWHA who have 
depression may still require specialty level care. Early identification of individuals who may 
not benefit from integrated care approaches and who will require specialty-level mental 
health care could lead to more cost-effective treatment. Among PLWHA who are receiving 
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depression care, response to depression treatment has been associated with employment 
status, viral load at initial treatment, increase in CD4 count during treatment, and lower 
mean baseline CD4 count at initiation of treatment (Primeau et al., 2013), although these 
factors have not been consistent across studies. More patient-centered measures of distress 
have not been examined in this population in regards to response to depression treatment. 
Such symptom-level factors (i.e. sleep difficulty, fatigue, anxiety, anhedonia, appetite, etc.) 
could provide clinicians with targets for treatment that could improve response to depression 
interventions.
Here we present a secondary analysis of data from a randomized controlled trial to evaluate 
the effectiveness of evidence-based antidepressant management integrated into HIV care. 
Our focus here is on baseline characteristics that might distinguish those individuals who 
will remit or respond to depression treatment sooner and those who may be more treatment 
resistant. We also examine factors at important time frames during the course of depression 
treatment in an effort to identify targets for more focused interventions. This information 
could help guide clinicians to identify such characteristics when making decisions about 
how to optimally treat an individual or when to refer a patient for more specialized mental 
health care over the course of depression treatment. Given this is a secondary analysis, our 
aim with this study was to identify potentially interesting questions that could be the topic of 
future, prospective, appropriately-powered studies.
2. Methods
Data for the present analysis come from a randomized controlled trial to evaluate the 
effectiveness of evidence-based antidepressant management integrated into HIV care in 
improving antiretroviral adherence (the SLAM DUNC Study), described in detail elsewhere 
(Pence et al., 2012). Briefly, HIV-infected patients receiving medical care at one of four 
U.S. infectious diseases clinics were eligible to participate if they were English-speaking, 
ages 18 – 65, screened positive for depression (score ≥ 10) on the Patient Health 
Questionnaire-9 (PHQ-9) (Spitzer et al., 1999), and were confirmed to have a current major 
depressive disorder on the Mini International Neuropsychiatric Interview (MINI) (Sheehan 
et al., 1998). Exclusion criteria included history of bipolar or psychotic disorder, failure of 
two or more adequate antidepressant trials in the current major depressive episode, or 
psychiatric presentation requiring immediate hospitalization or other acute intervention 
(Pence et al., 2012).
Eligible individuals who agreed to participate were randomized to receive either enhanced 
usual care for depression or a depression treatment model called Measurement-Based Care 
(MBC) (Adams et al., 2012). Data for the present analysis come only from individuals 
randomized to MBC. In the MBC arm, a clinically supervised depression care manager 
(DCM) completed regular assessments of depressive severity and antidepressant tolerability 
using standardized tools. The DCM then followed an evidence-based algorithm to provide 
antidepressant treatment recommendations (e.g. increase dose, maintain dose, switch 
medication) to the HIV provider, who made final decisions on the depression treatment plan. 
Participants randomized to the enhanced usual care arm could also receive depression 
treatment from their HIV provider or other sources, but no in-clinic decision support was 
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provided by the DCM. All participants provided written informed consent, and ethical 
approval was provided by Duke University, the University of North Carolina at Chapel Hill, 
and the University of Alabama at Birmingham.
2.1. Measures
Depressive severity over time was measured using the PHQ-9 (Kroenke et al., 2001). The 
PHQ-9 was administered monthly to participants in the MBC arm during the acute phase of 
treatment. Patients who achieved remission (PHQ-9 < 5) entered a maintenance phase, with 
PHQ-9 assessment every 3 months. Patients could also move to the maintenance phase if 
they and their provider were “satisfied” with their improvement and thought that further 
dose adjustments were unlikely to lead to further gains. We defined three antidepressant 
treatment outcomes: remission (our primary outcome, defined as PHQ-9 < 5), response (≥ 
50% improvement in PHQ-9 score from baseline), and clinically acceptable improvement 
(either remission or patient/provider “satisfaction”, as described above).
We investigated associations of all three depression treatment outcomes with three 
categories of predictors: demographic, mental health-related, and HIV-related. Demographic 
predictors considered were gender, marital status and education. Mental health-related 
predictors considered were depressive severity (PHQ-9 score), presence of psychiatric 
comorbidities (depression only; depression and anxiety only; depression and substance 
abuse only; or depression, anxiety and substance abuse), history of recurrent major 
depressive episode, specific types of anxiety diagnoses (panic disorder, post-traumatic stress 
disorder or generalized anxiety disorder), sleep difficulty, and fatigue. Analyses that 
included time-updated predictors also evaluated antidepressant side effect burden. Anxiety 
and substance use diagnoses and past depressive episodes were measured using the MINI 
(Sheehan et al., 1998). Presence or absence of self-reported sleep difficulty, anxiety, and 
fatigue were measured with the Patient-Reported Inventory of Side Effects (Rush et al., 
2004). Antidepressant side effect burden was measured using the Frequency, Intensity, and 
Burden of Side Effects Rating (FIBSER) on a scale from 0 to 6, with 0 indicating no side 
effects, 1–5 indicating minimal, mild, moderate, marked and severe side effects, and 6 
indicating inability to function due to side effects (Wisniewski et al., 2006). HIV predictors 
considered were ART use and adherence (on ART and adherent [no missed pills in the 
previous week], on ART and not adherent [any missed pills in the previous week], off 
ART), viral suppression (< 50 copies/mL), CD4 count and the number of years in care prior 
to the study start (≤ 1, 4 1– 5, > 5–10 and > 10 years).
2.2. Statistical analyses
We used Cox proportional hazards models to estimate bivariable hazard ratios relating 
predictors to depression treatment outcomes. We conducted exploratory analyses focused on 
measuring the magnitude of the association of a given variable on treatment outcomes, 
rather than the statistical significance of the variables (whether the 95% confidence intervals 
of the hazard ratios crossed the null). In this exploratory analysis, we considered HRs to be 
of a meaningful magnitude if they were ≤ 0.7 or ≥ 1.3. We felt that below and above these 
values suggest a potentially clinically meaningful association between the predictor and the 
outcome. While we determined all factors with HRs above or below these cutoffs to be 
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clinically meaningful, we also delineated those factors that had 95% CIs that excluded the 
null from those which had 95% CIs that did not exclude the null where appropriate. In the 
primary analysis, following the logic of an “intent-to-treat” analysis, participants were 
followed from study entry through the end of the study (one year), or until they experienced 
the outcome for that analysis, withdrew from the study (n = 11), or died (n = 2) (whichever 
date occurred first). In a second analysis, following the logic of an “as-treated” analysis, 
participants were followed from the date of antidepressant treatment initiation until 
outcome, withdrawal, death, or study end. In this analysis, participants who entered the 
study on depression treatment were followed from the date of their first antidepressant dose 
increase or switch after enrollment. In a third analysis, we restricted our attention to 
participants who had not remitted by 8 weeks after antidepressant treatment initiation or first 
adjustment, and assessed baseline and time-updated predictors of subsequent time to 
depression remission. We investigated the proportional hazards assumption and examined 
model fit using df betas to determine if there were influential observations.
2.3. Analysis sample
All study participants randomized to MBC were included in the primary analysis (n = 149). 
Only participants who initiated depression treatment or received their first treatment 
adjustment prior to experiencing the outcome for a particular analysis were included in the 
second analysis (n = 122–125, depending on the outcome). Finally, only participants who 
initiated depression treatment or received a treatment adjustment and did not remit within 8 
weeks were included in the third analysis (n = 104).
3. Results
3.1. Demographic characteristics of the study population
The demographic and clinical variables at baseline in the study population are shown in 
Table 1. Our population was predominantly male and most individuals were on ART. 
Almost 27% of patients on ART were non-adherent at baseline. The majority of patients had 
a viral load that was suppressed at baseline, but 31% did not. In terms of comorbidities, 
depression alone was present in 28% of patients, 40% had comorbid depression and anxiety, 
13% had comorbid depression and substance abuse, and 19% had comorbid depression, 
anxiety, and substance abuse. Over half (57%) reported a prior major depressive episode. 
The median PHQ9 score at baseline was 15, indicating moderate to moderately severe 
depression. Large numbers of patients reported sleep difficulty (85%), anxiety (72%), and 
fatigue (86%) as prominent symptoms on the PRISE rating scale.
3.2. Outcome experiences for patients
Over the 12 months of the study, 73 of 149 individuals achieved remission of their 
depression. The cumulative probability of first remission was 0.35, 0.63, and 0.78 at 3, 6, 
and 12 months, respectively. A total of 99 of 149 individuals achieved response over the 12 
months of the study. The cumulative probability of first response was 0.59, 0.79, and 0.96 at 
3, 6, and 12 months, respectively. A total of 79 individuals achieved first clinically 
acceptable improvement over the 12 months of the study. The cumulative probability of 
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reaching clinically acceptable improvement was 0.36, 0.65, and 0.82 at 3, 6, and 12 months, 
respectively.
3.3. Predictors of time to first remission
In an analysis of all patients in the treatment arm, when compared to patients with just 
depression alone, having comorbid anxiety and depression (HR 0.56, 0.32–0.98) or having 
comorbid depression with anxiety and substance abuse (HR 0.55, 0.27–1.13) at baseline 
predicted a slower time to first remission (Table 2). Further, having current generalized 
anxiety disorder (HR 0.60, 0.37–0.96) at baseline also predicted a slower time to first 
remission. Of these factors, having comorbid anxiety and depression and current generalized 
anxiety disorder had both a clinically meaningful magnitude of association and a 95% CI 
that excluded the null. Baseline factors that predicted a faster time to first remission included 
being on ART but being non-adherent (compared to those on ART and adherent; HR 1.53, 
0.93–2.53), having current panic disorder (HR 1.34, 0.73–2.49), having a history of a major 
depressive episode (HR 1.33, 0.83–2.12), or having been in HIV care for > 1–5 years (HR 
1.32, 0.7–2.46) or for >10 years (HR 1.65, 0.74–3.66) prior to study initiation (compared to 
those in HIV care ≤ year). Of note, we found no evidence of violation of the proportional 
hazards assumption or of overly influential individual observations.
In our study population, not all patients were receiving active depression treatment. Of the 
149 patients followed, 130 patients started antidepressant (AD) treatment or had an 
adjustment in their AD during the course of the study. Most of these patients (122) did not 
achieve first remission prior to initiation or adjustment of AD. Amongst those 122 
individuals, a bivariable analysis showed that when compared to those individuals who had 
depression only, having comorbid anxiety with depression (HR 0.51, 0.29–0.92) or having 
comorbid depression, anxiety, and substance abuse (HR 0.46, 0.21–1.01) led to a slower 
time to first remission in those who were in active treatment for depression (Table 3). 
Having comorbid anxiety with depression not only had a clinically meaningful magnitude of 
association with slower remission, but also a 95% CI that excluded the null. Having current 
generalized anxiety disorder (HR 0.64, 0.39–1.07) also predicted slower time to first 
remission. Baseline factors that predicted a faster time to first remission in those receiving 
active treatment included having been in HIV care for >1–5 years (HR 1.35, 0.68–2.7), >5–
10 years (HR 1.49, 0.73–3.04) or for more than 10 years (HR 2.54, 1.11–5.82) (compared to 
those in HIV care ≤1 year), having more than 12 years of education (HR 1.56, 0.94–2.6), 
being on ART and non-adherent with treatment (compared to those on ART and adherent; 
HR 1.58, 0.93–2.71), or having panic disorder (HR 1.36, 0.73–2.57). Of these, being in HIV 
care for >10 years had both a clinically meaningful magnitude of association, but also a 95% 
CI that excluded the null. We also examined symptoms at the time of AD initiation or 
adjustment that might predict course of treatment. Sleep difficulty (HR 0.55, 0.32–0.94) or 
fatigue (HR 0.63, 0.37–1.08) at this time point predicted slower time to remission (Table 3). 
Sleep difficulty had both a clinically meaningful magnitude of association, but also a 95% 
CI that excluded the null.
Of those 122 individuals who were in active treatment, 104 did not achieve first remission 
within 8 weeks of initiation or adjustment of AD. A total of 43 of these individuals 
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eventually achieved remission during the study. Baseline factors that predicted a slower time 
to first remission in this group included having co-morbid depression and anxiety (HR 0.68, 
0.33–1.41) or comorbid depression, anxiety and substance abuse (HR 0.64, 0.25–1.64), 
having a suppressed viral load (<50 copies/mL) (HR 0.55, 0.24– 1.24), having generalized 
anxiety disorder (HR 0.62, 0.33–1.16), or having fatigue (HR 0.58, 0.26–1.26) (Table 4). 
Baseline factors that predicted a faster time to first remission included being on ART and 
non-adherent to treatment (HR 1.30, 0.67–2.55), having >12 years of education (HR 1.58, 
0.85–2.93), having panic disorder (HR 1.63, 0.78–3.42), and having been in HIV care >10 
years (compared to those in HIV care ≤1 year; HR 1.78, 0.62–5.13). Examination of 
symptoms (as measure on PRISE) at the time of AD initiation or first adjustment showed 
that having sleep difficulty at that time predicted a slower time to first remission (HR 0.51, 
0.26– 0.98) with both clinically meaningful magnitude of association and a 95% CI that 
excluded the null (Table 4). Examination of symptoms at 8 weeks after AD initiation or first 
adjustment showed that having sleep difficulty (HR 0.68, 0.36–1.27), anxiety (HR 0.57, 
0.31–1.07), or fatigue (HR 0.52, 0.28–0.96) at that time predicted a slower time to first 
remission (Table 4). However, fatigue was the only factor that had both clinically 
meaningful magnitude of association and a 95% CI that excluded the null.
3.4. Predictors of time to first response or clinically acceptable improvement
In the analysis of all patients in the treatment arm, having comorbid depression and anxiety, 
or having comorbid depression, anxiety, and substance abuse both predicted a slower time to 
first response or clinically acceptable improvement (Table 2). Not being on ART or having 
sleep difficulty or fatigue at baseline predicted a slower time to first response, while having 
never been married, or having PTSD or GAD at baseline predicted a slower time to first 
clinically acceptable improvement. A baseline factor that predicted a faster time to first 
response or clinically acceptable improvement included having a history of a prior major 
depressive episode. Having panic disorder at baseline predicted a faster time to first 
response, while being on ART but non-adherent to treatment or being in HIV care for >1–5 
years, >5–10 years, or >10 years at baseline predicted a faster time to first clinically 
acceptable improvement.
Amongst those patients who did not achieve first response or first clinically acceptable 
improvement prior to AD initiation or adjustment, bivariable analysis showed that baseline 
predictors of slower time to first response or to first clinically acceptable improvement 
included having comorbid depression and anxiety or having comorbid depression, anxiety, 
and substance abuse, having been in HIV care for >10 years, or being divorced, widowed, or 
separated (Table 3). Baseline factors in this population that predicted a slower time to 
response only included not being on ART (compared to those on ART and adherent to 
treatment) or having sleep difficulty. Having never been married, having PTSD, having 
GAD, or having been in HIV care for >1–5 years or > 5–10 years at baseline predicted a 
slower time to first clinically acceptable improvement only. Baseline factors that predicted a 
faster time to first response or first clinically acceptable improvement in those receiving 
active treatment included having > 12 years of education or having been in HIV care for >10 
years. Having panic disorder or having a history of a prior major depressive episode at 
baseline predicted a faster time to first response. Being on ART but non-adherent to 
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treatment, or having been in HIV care for >1–5 years or >5 years predicted a faster time to 
clinically acceptable improvement. Examination of symptoms at the time of AD initiation or 
first adjustment showed that having sleep difficulty at that time predicted a slower time to 
response or clinically acceptable improvement, while having anxiety or fatigue at that time 
predicted a slower time to clinically acceptable improvement only (Table 3).
4. Discussion
Our study shows predictors of outcomes for HIV-infected individuals with depression 
enrolled in a MBC protocol from typical infectious disease clinics. As summarized in Fig. 1, 
several factors negatively affected recovery from depression in response to our intervention. 
We note that our study is an exploratory analysis and may not have been powered to 
determine predictors of recovery with clear statistical significance. However, we were still 
able to identify some predictors which had HRs with 95% CIs that excluded the null. We 
further identified other predictors that appeared to have clinically meaningful HRs, but had 
95% CIs that failed to exclude the null. While we cannot say with complete assurance that 
these factors truly predict slower or faster depression recovery, we highlight them as 
potential predictors that warrant further study.
As described previously, our population showed high levels of comorbid anxiety and/or 
substance abuse at baseline (Gaynes et al., 2015). Having comorbid anxiety and depression 
at baseline predicted a slower time to remission in all subjects and those in active depression 
treatment with a 95% CI that excluded the null (Fig. 1). In HIV-infected individuals, having 
comorbid anxiety with depression is significantly associated with a greater number of 
reported HIV symptoms, as well as worse mental health functioning (Gaynes et al., 2015). 
Further, having “anxious depression” was associated with lower remission and response 
rates in the STAR*D trial (Fava et al., 2008). Other studies have shown that patients with 
depression and “high anxiety” or who had an “anxious subtype” of depression showed either 
no difference or slightly higher remission and response rates than those with lower levels of 
anxiety (Arnow et al., 2015; Russell et al., 2001; Uher et al., 2011). However, in at least one 
study, this difference didn’t appear until after 6 weeks in treatment, and up until 6 weeks of 
treatment, the high anxiety group was actually less likely to achieve response, suggesting 
high levels of anxiety were associated with a slower initial response (Russell et al., 2001). A 
major caveat to some of these latter studies is that most of them specifically excluded 
individuals with DSM-diagnosed anxiety disorders, while our study and the STAR*D trial 
did not. Thus, our study may be more applicable to a more typical population in a HIV 
clinic. Interestingly, in our study, having GAD at baseline was predictive of a slower time to 
remission or clinically acceptable improvement, while having panic disorder at baseline was 
predictive of a faster time to remission or response (although the latter had a 95% CI that did 
not exlude the null). This distinction suggests that the quality of the anxiety a person 
experiences affected their response to depression treatment in this model. While our study is 
only an exploratory analysis, our findings suggest that identification of those patients with 
generalized anxiety at baseline in this model could trigger clinicians to be more aggressive 
about treatment of their depression or the need for early referral to specialized mental health 
care providers for these patients.
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Substance abuse is prevalent in PLWHA. In one US-based study, as many as 40% of HIV-
infected individuals admitted to illicit drug use in the prior 12 months (Bing et al., 2001). 
Alcohol use is also quite prevalent, with some estimates showing that 8–15% of HIV-
infected individuals in the US are classified as heavy drinkers, with 53% reporting a 1-
month prevalence of any current alcohol use (Galvan et al., 2002). Approximately 24% of 
PLWHA in the U.S. are in need of treatment for alcoholism or other substance abuse 
(Kumar et al., 2015). Not only is substance abuse highly prevalent in PLWHA, but it also 
has been associated with decreased anti-retroviral adherence (Arnsten et al., 2002; Berg et 
al., 2004; Braithwaite et al., 2005; Howard et al., 2002). Unfortunately, there have been few 
studies to date on outcomes in PLWHA and co-occurring substance abuse and depression. 
What has been published looked at injection-drug users specifically and has focused on 
depression as an independent variable affecting HIV outcomes (Arnsten et al., 2002; Carrieri 
et al., 2003). Depression is associated with poor adherence to antiretroviral therapy in this 
population (Avants et al., 2001; Waldrop-Valverde and Valverde, 2005), although one study 
suggested depression predicted HIV clinical progression among injection-drug users 
regardless of adherence (Bouhnik et al., 2005). Interestingly, in our study, the presence of 
substance abuse alone in depressed individuals did not appear to affect the rate of recovery 
from depression. This was somewhat surprising, given that the co-occurrence of substance 
abuse can negatively impact response to depression treatment in the general population 
(Bagby et al., 2002). However, the co-occurrence of both substance abuse and anxiety 
didoes appear to predict slower recovery from depression, although the 95% CI did not 
exclude the null. This result could be due to the effects of anxiety, which independently has 
a negative effect on the rate of depression recovery. However, given that comorbid 
psychiatric disorders can exacerbate substance abuse and vice versa, it is not surprising that 
the combination of all three diagnoses (depression, anxiety, and substance abuse) might lead 
to worse outcomes. A larger, prospective study is needed to definitively explore the effects 
of co-morbid substance abuse and anxiety on depression recovery.
Fatigue is one of the most common complaints of PLWHA, with an estimated prevalence 
between 55 and 65% (Barroso et al., 2010; Breitbart et al., 1998; Henderson et al., 2005; 
Voss, 2005). Fatigue can lead to difficulties with work, social activities, and activities of 
daily living. It is also associated with poor antiretroviral adherence and virologic failure (Al-
Dakkak et al., 2013; Marconi et al., 2013). Several studies have shown that several 
psychosocial variables are consistently correlated with fatigue in PLWHA, including 
depression, anxiety, PTSD, stressful life events, being unemployed, not being on 
antiretroviral therapy, and having fewer years since HIV diagnosis (Barroso et al., 2010; 
Jong et al., 2010). In our study, fatigue predicted a slower time to recovery in those involved 
in active treatment, as well as in non-remitters at 8 weeks post-treatment initiation/
adjustment. Given that adherence to ART treatment in our study was quite high, our findings 
suggest that fatigue contributes to poor treatment response regardless of treatment 
adherence. Targeting fatigue for treatment through psychological or pharmacologic 
treatment thus has the potential to improve depression treatment outcomes. There is little 
direct evidence in the literature specifically regarding treatment of fatigue in PLWHA, 
although it has been suggested that psychological treatments based in cognitive-behavioral 
therapy may be successful (Barroso et al., 2015; Jong et al., 2010). Modafanil and 
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armodafanil appear to have the most evidence in the pharmacologic treatment of fatigue in 
PLWHA and seem to have beneficial effects (McElhiney et al., 2010; Rabkin et al., 2011a,b, 
2004, 2010). Incorporation of these therapeutic interventions could potentially improve the 
rate of depression recovery in this population, although further study is needed.
Sleep difficulty at baseline in all patients and in just those getting active treatment predicted 
a slower time to depression response, although the 95% CIs failed to exclude the null. This 
suggests that sleep difficulty could affect an individual’s depression recovery in our model. 
This is not necessarily surprising, given sleep difficulty is known to be associated with a 
longer course of a major depressive episode and less response to pharmacologic or 
psychotherapeutic treatments (Dew et al., 1997; Franzen and Buysse, 2008; Pigeon et al., 
2008). Sleep difficulty as reported at the time of AD initiation or adjustment remained a 
predictor of slower remission, response, or clinically acceptable improvement, although 
again the 95% CIs failed to exclude the null. In addition, fatigue at the time of AD initiation 
or adjustment also predicted a slower recovery in patients receiving active treatment. These 
symptoms could represent targets for treatment that could potentially improve outcomes. For 
example targeting sleep hygiene, using conjunctive sedative-hypnotic medications, or 
selecting a sedating AD might be reasonable clinical decisions to potentially speed up 
recovery in this population, although further study is needed to confirm our results.
We also took a closer look at those individuals who did not enter remission 8 weeks after 
AD initiation or adjustment to see what factors might predict remission in this population, 
and therefore inform clinical decisions at 8 weeks about how best to proceed with treatment. 
None of the baseline factors had 95% CIs that excluded the null, but those that showed a 
clinically meaningful HR and predicted a slower time to remission were similar to those 
seen in the study population as a whole: namely comorbid depression and anxiety, comorbid 
depression, anxiety and substance abuse, or current GAD. Interestingly, sleep difficulty was 
the only symptom at the time of AD treatment initiation or adjustment that predicted a 
slower time to remission in this population. However, at 8 weeks after AD treatment 
initiation or adjustment, the presence of sleep difficulty, fatigue, or anxiety all predicted a 
slower time to remission, although only fatigue had a 95% CI that excluded the null (Fig. 1). 
These results could help guide clinicians in making treatment decisions at different points 
along the course of treatment. Using our treatment model, targeting sleep difficulty at the 
time of AD initiation or adjustment may quicken the time to recovery, while if patients have 
not responded by 8 weeks after AD initiation or adjustment, targeting sleep difficulty, 
anxiety and fatigue may be helpful. Further, those individuals who exhibit these symptoms 
may represent a more treatment-resistant population that could benefit from early referral to 
specialty mental health providers to optimize care. As such, focusing on these patient-
centered measurements of symptoms during care could potentially lead to overall better 
outcomes in this population.
Several baseline factors were predictive of a faster time to improvement in depression, 
although none were consistently found to have 95% CIs that excluded the null across the 
conditions examined (Fig. 1). Having had a prior major depressive episode was predictive of 
a faster time to remission, response, or clinically acceptable improvement in all patients, as 
well as a faster time to response or clinically acceptable improvement in those receiving 
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active treatment. It is unclear why patients with a history of depression might have a faster 
clinical improvement in response to our intervention. In our study, these patients did not 
appear to have higher rates of baseline comorbid anxiety disorders and did not have a faster 
or slower time to first AD initiation or adjustment. Further, we do not have any data that 
would suggest these individuals have a more “treatment-resistant” form of depression, only 
that they have a prior depressive episode. It may be that those individuals with a prior MDE 
in this study had developed better skills for dealing with depression due to their prior 
experience, or their provider was able to more quickly identify an efficacious medication 
strategy given prior response history. However, we are unable to definitively determine if 
these suggestions are true given our collected data.
Interestingly, being on ART but not being adherent to treatment at baseline was predictive of 
a faster time to remission, response, or clinically acceptable improvement in all subjects, as 
well as in the subset of those receiving active treatment. This result seems counterintuitive at 
first, but could be explained if by enrolling in the study, patients subsequently became more 
adherent to treatment, leading to a greater reduction in HIV symptom burden and 
improvement in mood. Another baseline factor that predicted a faster improvement in 
depression symptoms was if the patient had been engaged in HIV care for a longer period of 
time than 1 year. There is no clear reason for this effect, but potentially, those who have had 
HIV for longer periods of time may have less life stressors than those who are adjusting to a 
more recent diagnosis. Further, those engaged in long-term HIV treatment are likely to have 
formed strong relationships with providers and support staff that could be drawn on when 
treatment for depression is needed. Interestingly, amongst those patients receiving active 
treatment, having more than 12 years of education predicted a faster time to remission, 
response, or clinically acceptable improvement. However, a longer duration of education did 
not predict faster improvement in the analysis of all patients in the study. It is unclear why 
this might be the case, although it might be that those with more education may engage more 
fully in treatment or have more resources to utilize when involved in treatment. 
Unfortunately, there were no symptoms at the time of AD initiation or adjustment that 
predicted a faster time to any of the clinical outcomes. Amongst those individuals who did 
not remit by 8 weeks after AD initiation or adjustment, there were no symptoms at the 8 
week time point that predicted a faster time to ultimate remission.
Our study has limitations. Our analysis was conducted only within the MBC treatment arm 
of our study due to the availability of more monitoring with PHQ-9 screens in this arm. We 
were unable to assess whether our intervention had any effects on the rate of remission, 
response or clinically acceptable improvement relative to usual care. Further, there may be 
something about our intervention that could have affected the rate of recovery from 
depression in this population. We used PHQ-9 scores only to determine rates of remission or 
response, not true diagnostic criteria. Several items on the PHQ-9 are related to somatic 
symptoms (sleep, fatigue, appetite) that can be affected by several medical issues, including 
HIV infection or side effects from ART. In the palliative care population, for example, the 
presence of somatic symptoms has a very low positive predictive value for depression and 
scores on the PHQ-9 are not likely to respond to depression treatment alone (Rayner et al., 
2011). Thus, it is possible that in our population, some patients with high PHQ-9 scores do 
not truly have depression, and their response to our intervention targeting the disease would 
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be limited. A further limitation is that we conducted only exploratory analyses of our data to 
calculate hazard ratios, but did not do further statistical analyses to determine the statistical 
significance of these findings. However, given the relatively small size of our study, we felt 
focusing on the magnitude of effects may be more instructive, as the study was likely not 
powered to show statistical significance in these variables. In addition, we conducted only 
bivariable analyses, and multivariate analysis could potentially further delineate what 
baseline and time-updated factors are independently important to the rate of recovery from 
depression. Another limitation was out inability to determine if differences in depression 
recovery existed based on the specific antidepressant medication used or the dose of the 
medications. This was due to the fact that several different medications were used, and our 
numbers for any one medication were too small to produce meaningful statistical analysis. 
Finally, while we speculate that intervening on particular patient-reported symptoms at 
certain time points in treatment may lead to faster recovery, only a prospective 
interventional study could inform us if that is true.
In summary, our study presents important data on factors that could predict the rate of 
depression recovery in patients enrolled in a MBC treatment program. We have shown that 
comorbid psychiatric illness, as well as certain patient-centered factors play important roles 
in how quickly patients respond or remit with treatment. Further, targeting these patient-
centered symptoms at certain times during treatment, or using them as a signal for early 
referral to more specialized care could lead to improvements in patient outcomes. These data 
can help guide clinicians in their thinking about how best to treat patients in MBC models to 
target a more rapid recovery.
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GAD generalized anxiety disorder
HIV Human immunodeficiency virus
IQR Interquartile range
MBC measurement-based care
MINI Mini International Neuropsychiatric Interview (MINI)
N number of subjects
PHQ-9 Patient Healthcare Questionnaire-9
PLWHA people living with HIV/AIDS
PTSD posttraumatic stress disorder
PRISE Patient Rated Inventory of Side Effects
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Summary of factors associated with recovery from depression symptoms (remission, 
response or clinically acceptability), by time point at which they were measured. 
Abbreviations: MDE = Major Depressive Episode, HIV = Human Immunodeficiency Virus, 
ART = Antiretroviral Therapy.
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Table 1
Sociodemographic and mental health characteristics of 149 people enrolled in the SLAM-DUNC intervention 
arm.
Predictors of treatment response N (%) or median (IQR)
Psychiatric comorbidities
Depression only 42 (28.2)
Depression and anxiety 60 (40.3)
Depression and substance abuse 19 (12.8)
Depression, anxiety and substance abuse 28 (18.8)
Baseline ART and adherence
On ART and adherent 94 (63.1)
On ART and non-adherent 40 (26.9)
Not on ART 15 (10.1)
VL suppressed at baseline (<50 copies/mL)
No 91 (68.9)
Yes 41 (31.1)






Never married 85 (57.8)
Divorced, widowed, separated 31 (21.1)
Education
≤12 years 81 (55.5)
>12 years 65 (44.5)
Baseline PHQ-9 15 (12, 19)
History of major depressive episode 85 (57.1)
Current panic disorder 21 (14.2)
Current PTSD 28 (18.9)
Current GAD 67 (45.3)
Sleep difficulty-PRISE 119 (85.0)
Anxiety-PRISE 101 (72.1)
Fatigue-PRISE 121 (86.4)
Years in HIV care (prior to study start)
≤ 1 year 35 (23.5)
> 1–5 years 53 (35.6)
> 5–10 years 43 (28.9)
> 10 years 18 (12.1)
Abbreviations: ART = antiretroviral therapy; GAD = generalized anxiety disorder; HIV = Human immunodeficiency virus; IQR = Interquartile 
range; N = number of subjects; PHQ-9 = Patient Healthcare Questionnaire-9; PTSD = posttraumatic stress disorder; PRISE = Patient Rated 
Inventory of Side Effects; VL = Viral load.
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Table 2
Bivariable results for the association between baseline predictors and hazard of depression outcomes in all 
subjects (N = 149).
Baseline predictors of depression outcome
First remission N = 74
HR (95% CI)
First Response N = 99
HR (95% CI)
First clinically acceptable N = 79
HR (95% CI)
Slower course
Depression and anxiety 0.56 (0.32, 0.98) 0.64 (0.39, 1.04) 0.59 (0.35, 1.01)
Depression, anxiety, and substance abuse 0.55 (0.27, 1.13) 0.62 (0.34, 1.12) 0.52 (0.26, 1.04)
Current PTSD 0.73 (0.39, 1.36) 0.73 (0.43, 1.24) 0.68 (0.37, 1.26)
Current GAD 0.60 (0.37, 0.96) 0.72 (0.48, 1.08) 0.61 (0.38, 0.96)
Never married 0.78 (0.44, 1.39) 0.87 (0.53, 1.44) 0.69 (0.40, 1.18)
Not on ART 1.06 (0.47, 2.35) 0.65 (0.30, 1.42) 0.92 (0.42, 2.04)
Sleep difficulty, first contact-PRISE 0.85 (0.44, 1.62) 0.70 (0.41, 1.21) 0.80 (0.43, 1.48)
Anxiety, first contact-PRISE 0.75 (0.45, 1.26) 0.69 (0.44, 1.06) 0.76 (0.46, 1.26)
Faster course
On ART and non-adherent 1.53 (0.93, 2.53) 1.22 (0.79, 1.88) 1.49 (0.91, 2.41)
History of major depressive episode 1.33 (0.83, 2.12) 1.52 (1.01, 2.28) 1.32 (0.84, 2.08)
Current panic disorder 1.34 (0.72, 2.49) 1.35 (0.79, 2.32) 1.19 (0.64, 2.20)
Years in HIV care prior to study start
>1–5 years 1.32 (0.70, 2.46) 0.96 (0.57, 1.62) 1.45 (0.78, 2.69)
>5–10 years 1.17 (0.60, 2.29) 0.89 (0.51, 1.56) 1.53 (0.80, 2.92)
>10 years 1.65 (0.74, 3.66) 1.09 (0.55, 2.19) 1.66 (0.75, 3.70)
Bold = HR ≤ 0.7 or ≥ 1.3.
Abbreviations: AD = antidepressant; ART = antiretroviral therapy; CI = confidence interval; HR = Hazard ratio; GAD = generalized anxiety 
disorder; N = number of subjects; PTSD = posttraumatic stress disorder; PRISE = Patient Rated Inventory of Side Effects.
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Table 3
Bivariable results for the association between baseline or time-updated predictors (at time of antidepressant 
initiation or adjustment) and hazard of depression outcomes in patients in active treatment (N = 122–125).
Baseline predictors of depression outcome
First remission N = 63
HR (95% CI)
First response N = 83
HR (95% CI)




Depression and anxiety 0.51 (0.29, 0.92) 0.59 (0.35, 0.99) 0.56 (0.32, 0.98)
Depression, anxiety and substance abuse 0.46 (0.21, 1.01) 0.53 (0.27, 1.02) 0.44 (0.20, 0.95)
Not on ART 1.09 (0.46, 2.61) 0.65 (0.28, 1.52) 0.95 (0.40, 2.26)
Never married 0.75 (0.41, 1.40) 0.86 (0.50, 1.45) 0.62 (0.35, 1.11)
Divorced, widowed, separated 0.74 (0.36, 1.53) 0.66 (0.34, 1.27) 0.66 (0.33, 1.30)
Current PTSD 0.72 (0.38, 1.38) 0.72 (0.41, 1.25) 0.66 (0.35, 1.26)
Current GAD 0.64 (0.39, 1.07) 0.78 (0.50, 1.20) 0.67 (0.41, 1.10)
Sleep difficulty-PRISE 0.78 (0.38, 1.60) 0.64 (0.35, 1.16) 0.75 (0.38, 1.49)
Faster course
On ART and non-adherent 1.58 (0.93, 2.71) 1.21 (0.76, 1.93) 1.52 (0.91, 2.55)
Education>12 years 1.56 (0.94, 2.60) 1.65 (1.06, 2.56) 1.50 (0.92, 2.45)
History or a recurrent major depressive episode 1.19 (0.72, 1.97) 1.44 (0.93, 2.24) 1.26 (0.77, 2.04)
Current panic disorder 1.36 (0.73, 2.57) 1.37 (0.79, 2.37) 1.20 (0.64, 2.25)
Years in HIV care prior to study start
>1–5 years 1.35 (0.68, 2.70) 1.02 (0.58, 1.79) 1.45 (0.73, 2.87)
>5–10 years 1.49 (0.73, 3.04) 1.08 (9.58, 1.96) 2.01 (1.01, 4.01)
>10 years 2.54 (1.11, 5.82) 1.75 (0.86, 3.58) 2.65 (1.16, 6.07)
Predictors at time of AD initiation/first adjustment
Sleep difficulty-PRISE 0.55 (0.32, 0.94) 0.67 (0.41, 1.09) 0.58 (0.34, 0.98)
Anxiety-PRISE 0.71 (0.42, 1.19) 0.77 (0.49, 1.22) 0.65 (0.39, 1.07)
Fatigue-PRISE 0.63 (0.37, 1.08) 0.86 (0.52, 1.40) 0.55 (0.33, 0.93)
Bold = HR ≤ 0.7 or ≥ 1.3.
Abbreviations: AD = antidepressant; ART = antiretroviral therapy; CI = confidence interval; HR = Hazard ratio; GAD = generalized anxiety 
disorder; N = number of subjects; PTSD = posttraumatic stress disorder; PRISE = Patient Rated Inventory of Side Effects.
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Table 4
Bivariable results for the association between baseline or time-updated predictors and hazard of remission in 
subjects who did not remit at 8 weeks post-antidepressant (AD) initiation/first adjustment.
Baseline predictors of depression outcome
First remission N = 43
HR (95% CI)
Slower course
Depression and anxiety 0.68 (0.33, 1.41)
Depression, anxiety and substance abuse 0.64 (0.25, 1.64)
VL suppressed at baseline (<50 copies/mL) 0.55 (0.24, 1.24)
Current GAD 0.62 (0.33, 1.16)
Fatigue-PRISE 0.58 (0.26, 1.26)
Faster course
On ART and non-adherent 1.30 (0.67, 2.55)
Education>12 years 1.58 (0.85, 2.93)
Current panic disorder 1.63 (0.78, 3.42)
HIV care >10 years 1.78 (0.62, 5.13)
Predictors at time of AD initiation/first adjustment
Sleep difficulty-PRISE 0.51 (0.26, 0.98)
Predictors at 8 weeks after AD initiation/first
adjustment
Sleep difficulty-PRISE 0.68 (0.36, 1.27)
Anxiety-PRISE 0.57 (0.31, 1.07)
Fatigue-PRISE 0.52 (0.28, 0.96)
Abbreviations: AD = antidepressant; ART = antiretroviral therapy; CI = confidence interval; HR = Hazard ratio; GAD = generalized anxiety 
disorder; N = number of subjects; PRISE = Patient Rated Inventory of Side Effects; VL = viral load.
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